ArticleFrontiers in oncology2026
ESRP2 constrains EMT plasticity associated with ZEB1 expression in bladder cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epithelial-to-mesenchymal transition (EMT)-driven phenotypic plasticity promotes bladder cancer (BC) progression and therapy resistance. While EMT has been primarily associated with transcriptional reprogramming, the contribution of post-transcriptional mechanisms, particularly alternative splicing regulation, remains insufficiently explored. This study aimed to investigate the clinical significance and mechanistic role of epithelial splicing regulatory protein 2 (ESRP2) in BC. Methods: Integrative analyses of publicly available transcriptomic datasets (TCGA and GEO) were performed to evaluate the prognostic value of ESRP2 and its association with epithelial and mesenchymal phenotypes in BC cell lines. Functional assays, including ESRP2 knockdown and overexpression, were conducted to assess its impact on EMT marker expression, cellular behavior, and stemness-related features such as clonogenicity, spheroid formation, and cell surface marker expression. Results: High ESRP2 expression correlated with improved patient survival and an epithelial-like phenotype in BC models. ESRP2 loss induced mesenchymal marker expression and increased cell motility, whereas ESRP2 overexpression restored epithelial morphology, reduced migration, and suppressed anchorage-independent growth. Flow cytometry revealed no significant changes in CD44 expression but showed a moderate increase in CD133+ cells following ESRP2 overexpression, suggesting a qualitative shift in stem-like subpopulations rather than a global suppression of cancer stemness. Discussion: These findings identify ESRP2 as a key post-transcriptional regulator that constrains EMT-associated transcriptional programs linked to ZEB1 expression, thereby stabilizing epithelial identity in bladder cancer. Targeting alternative splicing may represent a promising therapeutic strategy to limit tumor aggressiveness and overcome treatment resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.